Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province

HANGZHOU, China and SHAOXING, China, April 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-04-04 17:10 4142

Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong

HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today...

2022-04-03 18:20 5151

Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to...

2022-03-30 18:26 3423

Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022

HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...

2022-03-27 18:30 5053

Business Update on ASC10, an Oral Double Prodrug against COVID-19

HANGZHOU and SHAOXING, China, March 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) toda...

2022-03-15 19:55 3921

Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year

HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis,...

2022-03-13 18:30 5007

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries

-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Be...

2022-03-01 17:30 4146

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-02-14 17:34 4867

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-02-13 18:30 5460

Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

* ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus varia...

2022-02-07 19:00 4562

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

* The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain pre...

2022-02-06 18:30 5475

Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2022-01-26 19:00 4352

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2022-01-23 18:35 5308

Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos

HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis") (HKEX...

2022-01-18 18:00 3804

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the ...

2022-01-17 18:12 5216

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today...

2022-01-13 17:30 4986

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-01-11 08:30 4376

Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-01-10 08:30 4452

Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH

* ASC43F was safe and well tolerated in healthy subjects with no clinically significant study dru...

2022-01-04 08:30 4541

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

- Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can...

2022-01-03 08:30 4845